Legal & General Group’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,299
Closed -$78K 3784
2021
Q1
$78K Buy
1,299
+488
+60% +$17.7K ﹤0.01% 2690
2020
Q4
$12K Hold
811
﹤0.01% 3292
2020
Q3
$9K Buy
+811
New +$13.9K ﹤0.01% 3290

Legal & General Group's PAND Position: Q2 2021 in Review

Legal & General Group sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 1,299 shares — an estimated $78K sold.

Legal & General Group first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $78K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • Legal & General Group reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 1,299 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $78K.
  • Legal & General Group first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Legal & General Group's Pandion Therapeutics Inc. Common Stock position peaked at $78K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.